Evaxion Biotech A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
1.750
+0.040 (2.34%)
May 20, 2025, 4:00 PM - Market closed
Evaxion Biotech Stock Forecast
EVAX's stock price has decreased by -90.59% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 2 professional analysts, the 12-month price target for Evaxion Biotech stock ranges from a low of $6.00 to a high of $14. The average analyst price target of $10 forecasts a 471.43% increase in the stock price over the next year.
Price Target: $10.00 (+471.43%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 2, 2025.
Analyst Ratings
The average analyst rating for Evaxion Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +700.00% | Apr 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +700.00% | Feb 20, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $35 → $6 | Strong Buy | Maintains | $35 → $6 | +242.86% | Feb 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +700.00% | Feb 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $140 | Strong Buy | Reiterates | $140 | +7,900.00% | Nov 1, 2024 |
Financial Forecast
Revenue This Year
248.88K
from 3.34M
Decreased by -92.56%
Revenue Next Year
4.87M
from 248.88K
Increased by 1,854.76%
EPS This Year
-2.99
from -9.85
EPS Next Year
-2.81
from -2.99
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 512,400 | 14.0M | 28.0M | ||
| Avg | 248,880 | 4.9M | 27.2M | ||
| Low | n/a | n/a | 26.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -84.7% | 5,525.2% | 475.5% | ||
| Avg | -92.6% | 1,854.8% | 459.1% | ||
| Low | - | - | 437.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.92 | -2.89 | 0.05 | ||
| Avg | -2.99 | -2.81 | 0.05 | ||
| Low | -3.02 | -2.70 | 0.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.